A study of IRESSA treatment beyond progression in addition to Chemotherapy versus Chemotherapy alone - IMPRESS

Exclusion Criteria

• - Prior chemotherapy or other systemic anti-cancer treatment (excluding gefitinib). Palliative bone radiotherapy must be completed at least 2 weeks before start of study treatment with no persistent radiation toxicity).
• - Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease
• - Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ or completely resected intramucosal gastric cancer
• -Any evidence of severe of uncontrolled systemic disease Treatment with an investigational drug within 4 weeks before randomization